Barr Pharmaceuticals is a specialty pharmaceutical company that develops, markets and sells both generic and proprietary (or branded) pharmaceutical products. Barr Pharmaceuticals has a deep, diverse and profitable generic product portfolio, and has diversified its operations by developing and acquiring several proprietary products. For the fiscal year ended June 30, 2005, Barr Pharmaceuticals recorded net earnings of $215 million on revenues of $1 billion. Of its $1 billion of revenues in fiscal 2005, $751 million were from sales of generic products, $279 million were from sales of proprietary products, and $17 million were attributed to revenues derived from co-promotion alliances, development agreements and other sources. Barr Pharmaceutical's business has two reportable segments: generic pharmaceuticals and proprietary pharmaceuticals. In the generic pharmaceutical segment, it currently manufactures and distributes more than 150 different dosage forms and strengths of over 75 different generic pharmaceutical products, including 22 oral contraceptive products, representing the largest category of its generic product portfolio.